Increased immunoreactive calcitonin in idiopathic hypercalciuria

J. L. Ivey, B. A. Roos, F. H. Shen, D. J. Baylink

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Serum immunoreactive calcitonin concentration (iCT) was determined in nine subjects with idiopathic hypercalciuria (IH), prior to and during oral phosphate supplementation (500 mg qid) to test the hypothesis that a renal phosphate leak was the primary defect resulting in IH in these patients. Prior to the oral phosphate supplementation, serum ICT was significantly elevated in the IH group, when compared to 26 normal individuals (75 ± 7 vs 45± 4 pg/ml, mean ± SE, P < .001). During oral phosphate treatment, however, serum iCT decreased to levels not significantly different from normals (39 ± 3 and 50 ± 5 pg/ml after 4 and 8 weeks, respectively). When data prior to and during phosphate supplementation were pooled, there was a significant correlation (r = .70, N = 26, P < .001) between serum iCT and serum calcium. These observations suggest that the increased serum iCT in these subjects was a response to slight elevations in serum calcium, which are the result of normal physiological mechanisms to correct the renal phosphate leak.

Original languageEnglish
Pages (from-to)39-42
Number of pages4
JournalMetabolic Bone Disease and Related Research
Volume3
Issue number1
DOIs
StatePublished - Jan 1 1981
Externally publishedYes

Fingerprint

Hypercalciuria
Calcitonin
Phosphates
Serum
Calcium
Kidney

Keywords

  • Calcitonin
  • Idiopathic Hypercalciuria
  • Oral Phosphate
  • Renal Phosphate Leak

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Surgery

Cite this

Increased immunoreactive calcitonin in idiopathic hypercalciuria. / Ivey, J. L.; Roos, B. A.; Shen, F. H.; Baylink, D. J.

In: Metabolic Bone Disease and Related Research, Vol. 3, No. 1, 01.01.1981, p. 39-42.

Research output: Contribution to journalArticle

Ivey, J. L. ; Roos, B. A. ; Shen, F. H. ; Baylink, D. J. / Increased immunoreactive calcitonin in idiopathic hypercalciuria. In: Metabolic Bone Disease and Related Research. 1981 ; Vol. 3, No. 1. pp. 39-42.
@article{191a47325f2540809fad1c7994e845e4,
title = "Increased immunoreactive calcitonin in idiopathic hypercalciuria",
abstract = "Serum immunoreactive calcitonin concentration (iCT) was determined in nine subjects with idiopathic hypercalciuria (IH), prior to and during oral phosphate supplementation (500 mg qid) to test the hypothesis that a renal phosphate leak was the primary defect resulting in IH in these patients. Prior to the oral phosphate supplementation, serum ICT was significantly elevated in the IH group, when compared to 26 normal individuals (75 ± 7 vs 45± 4 pg/ml, mean ± SE, P < .001). During oral phosphate treatment, however, serum iCT decreased to levels not significantly different from normals (39 ± 3 and 50 ± 5 pg/ml after 4 and 8 weeks, respectively). When data prior to and during phosphate supplementation were pooled, there was a significant correlation (r = .70, N = 26, P < .001) between serum iCT and serum calcium. These observations suggest that the increased serum iCT in these subjects was a response to slight elevations in serum calcium, which are the result of normal physiological mechanisms to correct the renal phosphate leak.",
keywords = "Calcitonin, Idiopathic Hypercalciuria, Oral Phosphate, Renal Phosphate Leak",
author = "Ivey, {J. L.} and Roos, {B. A.} and Shen, {F. H.} and Baylink, {D. J.}",
year = "1981",
month = "1",
day = "1",
doi = "10.1016/S0221-8747(81)80021-5",
language = "English",
volume = "3",
pages = "39--42",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Increased immunoreactive calcitonin in idiopathic hypercalciuria

AU - Ivey, J. L.

AU - Roos, B. A.

AU - Shen, F. H.

AU - Baylink, D. J.

PY - 1981/1/1

Y1 - 1981/1/1

N2 - Serum immunoreactive calcitonin concentration (iCT) was determined in nine subjects with idiopathic hypercalciuria (IH), prior to and during oral phosphate supplementation (500 mg qid) to test the hypothesis that a renal phosphate leak was the primary defect resulting in IH in these patients. Prior to the oral phosphate supplementation, serum ICT was significantly elevated in the IH group, when compared to 26 normal individuals (75 ± 7 vs 45± 4 pg/ml, mean ± SE, P < .001). During oral phosphate treatment, however, serum iCT decreased to levels not significantly different from normals (39 ± 3 and 50 ± 5 pg/ml after 4 and 8 weeks, respectively). When data prior to and during phosphate supplementation were pooled, there was a significant correlation (r = .70, N = 26, P < .001) between serum iCT and serum calcium. These observations suggest that the increased serum iCT in these subjects was a response to slight elevations in serum calcium, which are the result of normal physiological mechanisms to correct the renal phosphate leak.

AB - Serum immunoreactive calcitonin concentration (iCT) was determined in nine subjects with idiopathic hypercalciuria (IH), prior to and during oral phosphate supplementation (500 mg qid) to test the hypothesis that a renal phosphate leak was the primary defect resulting in IH in these patients. Prior to the oral phosphate supplementation, serum ICT was significantly elevated in the IH group, when compared to 26 normal individuals (75 ± 7 vs 45± 4 pg/ml, mean ± SE, P < .001). During oral phosphate treatment, however, serum iCT decreased to levels not significantly different from normals (39 ± 3 and 50 ± 5 pg/ml after 4 and 8 weeks, respectively). When data prior to and during phosphate supplementation were pooled, there was a significant correlation (r = .70, N = 26, P < .001) between serum iCT and serum calcium. These observations suggest that the increased serum iCT in these subjects was a response to slight elevations in serum calcium, which are the result of normal physiological mechanisms to correct the renal phosphate leak.

KW - Calcitonin

KW - Idiopathic Hypercalciuria

KW - Oral Phosphate

KW - Renal Phosphate Leak

UR - http://www.scopus.com/inward/record.url?scp=0019348311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019348311&partnerID=8YFLogxK

U2 - 10.1016/S0221-8747(81)80021-5

DO - 10.1016/S0221-8747(81)80021-5

M3 - Article

C2 - 7266365

AN - SCOPUS:0019348311

VL - 3

SP - 39

EP - 42

JO - Bone

JF - Bone

SN - 8756-3282

IS - 1

ER -